Metastatic Burden in Hormone-Naive Prostate Cancer: A Tale of Two Subgroups

被引：1
|
作者：
Haran, A. M. [1 ,2 ,3 ,4 ]
Ali, A. [1 ,2 ,3 ]
Clarke, N. W. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Manchester, Div Canc Sci, Genitourinary Canc Res Grp, Manchester, Lancs, England
[2] Univ Manchester, Div Canc Sci, FASTMAN Ctr Excellence, Manchester, Lancs, England
[3] Christie NHS Fdn Trust, Dept Surg, Wilmslow Rd, Manchester M20 4BX, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Urol, Manchester, Lancs, England
来源：
CLINICAL ONCOLOGY | 2020年 / 32卷 / 03期
关键词：
D O I：
10.1016/j.clon.2019.12.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：209 / 212
页数：4
相关论文
共 50 条
  • [1] Treatment of hormone-naive metastatic prostate cancer
    Hamilou, Zineb
    Saad, Fred
    Fizazi, Karim
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 334 - 338
  • [2] Genomic landscape of metastatic hormone-naive prostate cancer
    Mizuno, Kei
    Akamatsu, Shusuke
    Goto, Takayuki
    Kobayashi, Takashi
    Ogawa, Osamu
    CANCER SCIENCE, 2021, 112 : 656 - 656
  • [3] Circulating tumor cell in hormone-naive metastatic prostate cancer
    Kanayama, M.
    Nagaya, N.
    Nagata, M.
    Horie, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial
    Buelens, Sarah
    Poelaert, Filip
    Dhondt, Bert
    Fonteyne, Valerie
    De Visschere, Pieter
    Ost, Piet
    Verbeke, Sofie
    Villeirs, Geert
    De Man, Kathia
    Rottey, Sylvie
    Decaestecker, Karel
    Lumen, Nicolaas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (04) : 158.e13 - 158.e20
  • [5] The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
    Aoun, Fouad
    El Rassy, Elie
    Sleilaty, Ghassan
    Assi, Tarek
    Bakouny, Ziad
    Kattan, Joseph
    FUTURE ONCOLOGY, 2017, 13 (30) : 2785 - 2790
  • [6] Medical treatment of patients with hormone-naive metastatic prostate cancer: what's new?
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 192 - 192
  • [7] Trends in the use of local intervention for metastatic hormone-naive prostate cancer: A multicenter retrospective study
    Tanaka, Ryuma
    Hatakeyama, Shingo
    Narita, Shintaro
    Sakurai, Toshihiko
    Tanaka, Toshikazu
    Miura, Hikari
    Oishi, Takuya
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishidoya, Shigeto
    Mitsuzuka, Koji
    Ito, Akihiro
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (11) : 969 - 976
  • [8] In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not Yet
    Armstrong, Andrew J.
    ONCOLOGY-NEW YORK, 2014, 28 (10): : 881 - +
  • [9] Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naive Prostate Cancer in Japanese Men
    Nakagawa, Ryunosuke
    Iwamoto, Hiroaki
    Makino, Tomoyuki
    Naito, Renato
    Kadomoto, Suguru
    Akatani, Norihito
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Izumi, Kouji
    Kadono, Yoshifumi
    Takamatsu, Atsushi
    Yoshida, Kotaro
    Mizokami, Atsushi
    CANCERS, 2022, 14 (19)
  • [10] A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer
    Corn, Paul G.
    Zhang, Miao
    Nogueras-Gonzalez, Graciela M.
    Xiao, Lianchun
    Zurita, Amado J.
    Subudhi, Sumit K.
    Tu, Shi-Ming
    Aparicio, Ana M.
    Coarfa, Cristian
    Rajapakshe, Kimal
    Huang, Shixia
    Navone, Nora M.
    Lin, Sue-Hwa
    Wang, Guocan
    Ramachandran, Sumankalai
    Titus, Mark A.
    Panaretakis, Theocharis
    Gallick, Gary E.
    Efstathiou, Eleni
    Troncoso, Patricia
    Logothetis, Christopher
    CLINICAL CANCER RESEARCH, 2020, 26 (05) : 990 - 999
12345